Compugen Ltd (CGEN): Shareholders' Equity
$102.73M
As of 2025-12-31
+9.8%
3-year compound annual growth
-3.0%
5-year compound annual growth
+1.3%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $102.73M | +87.1% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $54.91M | -16.2% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $65.56M | -15.6% | 2026-03-02, Balance as of period end |
| 2022-12-31 | $77.68M | -27.2% | 2025-03-04, Balance as of period end |
| 2021-12-31 | $106.69M | -10.9% | 2024-03-05, Balance as of period end |
| 2020-12-31 | $119.78M | +212.6% | 2023-08-23, Balance as of period end |
| 2019-12-31 | $38.32M | +2.9% | 2022-02-28, Balance as of period end |
| 2018-12-31 | $37.24M | +27.1% | 2021-02-25, Balance as of period end |
| 2017-12-31 | $29.30M | -53.9% | 2020-02-24, Balance as of period end |
| 2016-12-31 | $63.52M | -29.3% | 2019-03-21, Balance as of period end |
| 2015-12-31 | $89.90M | -15.3% | 2018-03-27, Balance as of period end |
| 2014-12-31 | $106.12M | +232.8% | 2017-02-16, Balance as of period end |
| 2013-12-31 | $31.89M | +80.4% | 2016-03-07, Balance as of period end |
| 2012-12-31 | $17.67M | -9.7% | 2015-03-12, Balance as of period end |
| 2011-12-31 | $19.58M | -30.8% | 2014-02-18, Balance as of period end |
| 2010-12-31 | $28.29M | +3.2% | 2013-03-21, Balance as of period end |
| 2009-12-31 | $27.40M | n/a | 2012-03-14, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Compugen Ltd (CGEN) | 2025-12-31 | $102.73M | +87.1% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $1.13B | +9.3% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $178.13M | -58.3% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $112.21M | +34.7% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $765.28M | -33.5% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | -$5.79M | n/m |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $505.66M | -1.0% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $3.94M | +4.4% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $241.54M | +257.6% |
Compare CGEN, RXRX, AUTL, BDTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗